Literature DB >> 8102617

Long-term high-dose neuroleptic treatment: who gets it and why?

M I Krakowski1, M Kunz, P Czobor, J Volavka.   

Abstract

OBJECTIVE: High doses of neuroleptic medication are still administered to many patients, although many studies have shown the effectiveness of low-dose strategies. The purposes of the study were to determine whether and in what ways high-dose patients differed from patients on regular dosages and whether the higher dosages were more effective.
METHODS: In a case-control study at two large state hospitals, 38 high-dose patients were compared with 29 regular-dose patients.
RESULTS: The high-dose patients had a persistent course of illness, with severe chronic symptoms resulting in hospitalizations of much longer duration than those of the regular-dose patients. The high-dose patients evidenced more regressed functioning and were more violent. To control these behaviors, clinicians increased neuroleptic dosages.
CONCLUSIONS: The high-dose patients represented a subgroup of chronic regressed and violent patients. Clinicians prescribed high dosages and continued to use them despite a lack of clear evidence that such treatment is effective.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8102617     DOI: 10.1176/ps.44.7.640

Source DB:  PubMed          Journal:  Hosp Community Psychiatry        ISSN: 0022-1597


  4 in total

Review 1.  Understanding antipsychotic "atypicality": a clinical and pharmacological moving target.

Authors:  Gary Remington
Journal:  J Psychiatry Neurosci       Date:  2003-07       Impact factor: 6.186

Review 2.  Medication errors in psychiatry: a comprehensive review.

Authors:  Ric M Procyshyn; Alasdair M Barr; Tracey Brickell; William G Honer
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

Review 3.  Atypical psychotropic medications and their adverse effects: a review for the African-American primary care physician.

Authors:  Rahn Kennedy Bailey
Journal:  J Natl Med Assoc       Date:  2003-02       Impact factor: 1.798

4.  Optimizing dosing in atypical neuroleptic monotherapy.

Authors:  Fabien Trémeau; Leslie Citrome
Journal:  Dialogues Clin Neurosci       Date:  2002-12       Impact factor: 5.986

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.